RT Journal Article ID 171ce94b0b6a30d5 A1 Qadir, Muhammad Imran A1 Zafar, Maria T1 TSG101: Tumor Susceptibility Gene 101 (tsg101) Product−Role in Therapy Against HIV/AIDS JF Critical Reviews™ in Eukaryotic Gene Expression JO CRE YR 2017 FD 2017-09-29 VO 27 IS 3 SP 237 OP 246 K1 tumor susceptibility gene 101 (tsg101) K1 HIV K1 monoclonal antibody K1 CB8-2 K1 HIV/AIDS therapy K1 UEV, TSG101 AB HIV infection presents a major community health hazard, partially because the HIV virus is capable of evading antiretroviral therapies. Most anti-HIV drugs were intended to target virus-encoded mechanisms; however, some host-encoded molecules comparatively execute a vital role in the life cycle of virus. Thus, these might be considered as target sites for antiviral agents. TSG101 is important among these antiviral therapies because, as a cytoplasmic molecule, it facilitates viral budding and release. In this review, HIV-infected cells have TSG101 on their surface and thus can be used in antibody-based therapies. The development of a monoclonal antibody CB8-2 lessens the assembly of viruses from infected cells. This mechanism represents the potential use of TSG101-directed antibodies to fight against AIDS. PB Begell House LK https://www.dl.begellhouse.com/journals/6dbf508d3b17c437,3e1db9ff199ae23c,171ce94b0b6a30d5.html